- Home
- FENC vs PRLD Comparison
FENC vs PRLD Comparison
Compare FENC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | PRLD |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.4M | 218.0M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FENC | PRLD |
|---|---|---|
| Price | $6.50 | $4.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $14.50 | $5.67 |
| AVG Volume (30 Days) | 133.5K | ★ 459.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,642,000.00 | $12,140,000.00 |
| Revenue This Year | $65.12 | $320.10 |
| Revenue Next Year | $41.08 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $5.65 | $0.73 |
| 52 Week High | $9.92 | $5.54 |
Technical Indicators
Market Signals| Indicator | FENC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 57.87 |
| Support Level | $5.65 | $1.17 |
| Resistance Level | $8.09 | $5.54 |
| Average True Range (ATR) | 0.34 | 0.67 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 48.51 | 53.94 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.